Skip to content

D&A at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$172.3M+11.6%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$1.57M0.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$661K+13.6%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$4.22M+57.1%
Arrowhead Research logo
Arrowhead ResearchARWR
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's D&A?
Alkermes (ALKS) reported D&A of $11.68M in Q1 2026.
What is the long-term trend for Alkermes's D&A?
Over 4 years (2021 to 2025), Alkermes's D&A has grown at a -43.7% compound annual growth rate (CAGR), from $38.15M to $3.85M.
What does D&A mean?
The non-cash expense that accounts for the declining value of physical assets and intangible property over time.
How do you interpret D&A?
An increase often follows significant capital investments or acquisitions, while a decrease may suggest aging assets or fully amortized intellectual property.
How does D&A compare across companies?
Commonly added back to operating income to calculate EBITDA, allowing for comparison across companies with different capital structures.